Showing 4031-4040 of 4164 results for "".
- Sight Sciences Announces $30 Million Financinghttps://modernod.com/news/sight-sciences-announces-30-million-financing/2477405/Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMN
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2020 Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2020-annual-conference/2477365/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 10-11) and 29th annual General Conference (September 12-13) at the Hyatt Regency Columbus in Columbus, Ohio. “This year’s conference them
- Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Trial of Dry Eye Disease Drug Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-statistically-significant-results-in-stride-3-trial-of-dry-eye-disease-drug-eysuvis/2477360/Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met b
- ReNeuron Announces Positive Long-Term Data in Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-announces-positive-long-term-data-in-retinitis-pigmentosa-trial/2477320/ReNeuron Group has announced positive long-term data from the ongoing phase 1/2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP) and plans to expand the ongoing study. In October 2019, positive interim efficacy data from p
- Could a Hormone be Used to Treat Eye Disease?https://modernod.com/news/could-a-hormone-be-used-to-treat-eye-disease/2477314/John A. Moran Eye Center researchers continue to shed new light on the potential of the hormone erythropoietin (EPO) to treat eye disease. EPO increases red blood cell production, and is already used clinically to treat anemia. However, more recently EPO is being recognized for other properties,
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- Bausch Health and Clearside Biomedical Announce Publication of Pivotal Phase 3 Data on Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-publication-of-pivotal-phase-3-data-on-xipere/2477264/Bausch Health Companies and Clearside Biomedical announced that results from the randomized, controlled, double-masked phase 3 clinical trial (PEACHTREE study) of Xipere (triamcinolone acetonide suprachoroidal injectable suspension), have been published in Ophthalmology.1 Xiper
- FDA Accepting Less Data, More Surrogate Endpoints in Trialshttps://modernod.com/news/fda-accepting-less-data-more-surrogate-endpoints-in-trials/2477241/Over the last four decades, the FDA has loosened its requirements for approving new drugs, increasingly accepting less data and more surrogate endpoints in clinical trials, and shortening its reviews, according to a new analysis, as reported</
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati